Menu
210521_Toraymyxin-EAA-homepage_653x337px

Sepsis and septic shock

TORAYMYXIN®

State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with high mortality and a significant economic burden on the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000-fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function, and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA-approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.

chronic-kidney-disease-653x337

Chronic kidney disease

TORAY PMMA FILTRYZER

A personalized therapy based on the individual needs of each patient

Hemofeel_Web_EN_653x337px

Acute kidney injury

HEMOFEELTM

HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on

240521_SMART2024_653x337px

SMART Meeting 2024 – Milan

The 35th SMART Meeting (Smart Meeting Anesthesia Resuscitation Intensive Care) is approaching and will take place from May 29 to 31, 2024, in Milan—Allianz MiCO.
We are partnering with SMART, and on May 29, we will support the lunch session “Extracorporeal organ support in critically ill patients”.

PROLUNG-nikkiso_653x337px

NIKKISO EUROPE and Estor S.p.A announce a strategic partnership

Milano, 23 October 2023 – A strategic partnership between Nikkiso Europe Group (NEG) and Estor S.p.A has been announced concerning the distribution of ProLUNG® Extracorporeal CO2 Removal System (Estor S.p.A – Italy) in selected countries.

221027-SIAARTI-ICARE_653x337px

SIAARTI – ICARE – MILAN

The 76th National Congress of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI) takes place in Milan from 28 to 30 October 2022. Estor is a partner of SIAARTI and, in addition to our presence with an exhibition area, we will support the symposium Advanced Blood Purification Therapies nel paziente critico settico” on 28 October.